ABSTRACT
Peer mentorship is a mutually beneficial relationship that allows two individuals who are at approximately the same experience level to interact with one another with the goal of providing personal, professional, or both types of support. It has been found that peer mentorship within academic settings have generally positive retention, persistence, and student experience outcomes for both mentors and mentees. While peer mentoring research and initiatives are growing, very few instances exist of determining student perceived needs regarding peer mentorship. As such, at a western institution in the United States, students were surveyed to self-report their perceived peer mentorship needs. This survey occurred during Fall 2021, just after the onset of the COVID-19 pandemic. Out of 223 participants, 79 students indicated that they currently had a peer mentor at the time the survey was administered. Students were given both a definition and examples of peer mentorship before indicating they had a peer mentor. Their mentors may have been formally assigned through an existing program at the college of engineering of interest or informally obtained through their own efforts. These 79 participants were asked what additional support they wish their peer mentor could provide. Through phenomenological analysis of open-ended responses, common avenues for additional support were determined. These findings allowed for development of recommendations for shaping the future implementation of more targeted and beneficial peer mentoring initiatives. The recommendations include providing flexibility in peer mentorship, training on resources and events, and a variety of peer mentoring opportunities early and consistently. © 2022 SEFI 2022 - 50th Annual Conference of the European Society for Engineering Education, Proceedings. All rights reserved.
ABSTRACT
In the midst the COVID-19 pandemic, and given the imminence of oxygen shortages in Colombia, the Knowledge Management and Transfer Network, made up of 19 scientific societies, health institutions, and universities, generates an update to the document led by the Colombian Association of Critical Medicine and includes new evidence-informed guidelines for the rational management of oxygen therapy, as well as basic and advanced devices for oxygen therapy. The recommendations refer to five topics: goal-oriented rational use of oxygen, standardization of follow-up and dose adjustment, effective use of oxygen therapy devices, rational use of invasive mechanical ventilation, and rational use of extracorporeal oxygenation membrane therapy. When exercising their judgment, it is expected that professionals and care teams will take into account these guidelines to make rational and safe use of oxygen therapy and its basic and advanced devices, together with the individual needs and preferences of the people who are under their care. © 2021 Asociación Colombiana de Medicina Crítica y Cuidado lntensivo
ABSTRACT
Background: Data on the effect of secukinumab on the humoral response to the BNT162b2 mRNA vaccine are limited. Objectives: We aimed to assess prospectively the humoral response to the BNT162b2 mRNA vaccine in patients with spondyloarthritis (SpA) treated with secukinumab in comparison to immunocompetent controls. Methods: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) treated with secukinumab for at least 3 months and immunocompetent controls were vaccinated with two-dose regimen of the BNT162b2 mRNA vaccine. Clinical and laboratory assessments were performed at 2-8 weeks [SpA: 37 on secukinumab, (median age 53% female), 122 controls (median age 53, 51% female)], and 6 months [SpA: 27 on secukinumab, 116 controls] after the second vaccine dose. A subgroup of patients (22 SpA on secukinumab, 45 controls) were evaluated after the third vaccine dose. The seropositive response was defned as a detectable S1/S2 IgG ≥15 binding antibody units (BAU)/ml. Results: The two-dose vaccine regimen induced a similar immunogenic response in patients and controls refected by the seropositivity rates of 100% in both groups. After six months, the rate of seropositivity remained as high as 96% in both secukinumab-treated patients and immunocompetent controls. The decline of S1/S2 IgG titer within six months was similar in controls and secukinumab-treated patients,-66.4 (95% CI {-70.9,-39.9}) and-55 BAU/ml (95% CI {-95.42,-36.87)). Following the third vaccine, the seropositivity rate increased to 100 % in both groups. At all-time points, S1/S2 IgG titers were similar in secukinumab treated patients and immunocompetent controls (Figure 1). Conclusion: SpA patients treated with secukinumab consistently demonstrated an adequate humoral response to the BNT162b2 mRNA vaccination similar to immunocompetent controls, both short-term and within six months after two vaccine doses and after the third vaccine dose.